Market overview

Prostate cancer – a significant health challenge

Prostate cancer is a significant health challenge. Approximately 13% of all men are expected to be diagnosed with prostate cancer in their lifetime. In 2022 alone, 730,000 new cases were reported in Europe and North America. The global prostate cancer treatment market is valued at approximately USD 12 billion by 2025. Forecasts suggest an annual growth rate of 8.4% from 2023 to 2030. Market expansion is driven by the increasing incidence of prostate cancer, advancements in screening methods and research, leading to development of new therapeutic methods.

Impact on quality of life

Current treatments can cause significant side effects that affect patients’ quality of life.

Variety of cases

Prostate cancer is a complex disease with varying cases that require different treatment methods to effectively manage the disease.

Rising incidence

Early onset prostate cancer has increased and is expected to continue to increase, posing a major health challenge.

Primary localised prostate cancer

Today, common treatment methods for primary localised prostate cancer include, for example, active surveillance, where the patient’s cancer is regularly monitored, and possible treatment is performed if needed. Other treatments for localised prostate cancer include, for example, radiation or surgery to remove the cancer. Although these treatments effectively remove the cancer, they are often associated with side effects, which negatively affect the patient’s quality of life, such as impotence and incontinence. About 70 percent of all cases of prostate cancer are localised prostate cancer.

Patients with localised cancer have cancers with different levels of risk. SpectraCure sees the potential to be able to offer a favorable alternative for a large proportion of patients at medium risk.

Recurrence of prostate cancer

In cases of prostate cancer recurrence following previous radiotherapy, there are currently limited treatment options available. Surgery is associated with complications, and further radiation is not feasible due to the tumours’ resistance to radiation. Consequently, the treatment of prostate cancer post-radiotherapy is contentious, as many existing methods entail significant side effects. Studies indicate that approximately 20 percent of patients experience relapse following completed radiotherapy.


Given these challenges, alternative treatment methods are being sought for this patient category. The potential advantages offered by SpectraCure’s treatment, such as a reduced side effect profile and the possibility of repeating the treatment if necessary, makes it a promising alternative for these patients.